Gemcitabine and nab-Paclitaxel combined with afatinib in metastatic pancreatic cancer – Results of a phase 1b clinical trial

The combination of gemcitabine/nab-paclitaxel is an established standard treatment in the first-line treatment of metastatic ductal adenocarcinoma of the pancreas (mPDAC). Afatinib, an oral second-generation pan ErbB family tyrosine kinase inhibitor, has shown promising pre-clinical signs in the treatment of pancreatic cancer. The aim of this phase 1b trial was to determine the maximum tolerated dose (MTD) of afatinib in combination with gemcitabine/nab-paclitaxel in patients with mPDAC.

Source: European Journal of Cancer - February 15, 2024 Category: Cancer & Oncology Authors: Danmei Zhang, C. Benedikt Westphalen, Michael Quante, Dirk T. Waldschmidt, Swantje Held, Fabian K ütting, Klara Dorman, Kathrin Heinrich, Lena Weiss, Myrto Boukovala, Michael Haas, Stefan Boeck, Volker Heinemann, Victoria Probst Tags: Original Research Source Type: research